Theoretically, patients with hepatitis might benefit more from PD1/PD-L1 antibodies based on the phenomenon that high levels of T cells in HBV-infected patients may enhance the sensitivities of PD-1 antibodies, and PD-1 antibodies could also evoke the immune system to defend against the virus (37). This evidence concerns the gene PDCD1 and hepatitis A virus infection.